Onego Bio will become the second tenant at Jefferson County’s Food and Beverage Innovation Campus. The proposed Jefferson site will be Onego Bio’s flagship manufacturing facility, dedicated to producing Bioalbumen®, a fermentation-derived egg protein powder. 

Onego Bio, a Finnish-U.S. food ingredient company, announced the submission of its Generally Recognized as Safe (GRAS) notification to the U.S. Food and Drug Administration (FDA) for its non-animal ovalbumin, produced through precision fermentation using Trichoderma reesei, and branded as Bioalbumen®.

The 5,000-square-foot facility will serve as the company’s U.S. commercial headquarters, housing office space alongside a state-of-the-art test kitchen and cutting-edge quality lab facilities.

Onego Bio, the producer of Bioalbumen®, has been awarded $2 million in funding from the United States Department of Defense’s (DoD’s) Distributed Bioindustrial Manufacturing Program (DBIMP). The funding from this program supports the advancement of biomanufacturing infrastructure across the United States, strengthening the domestic supply of key materials and ingredients. 

Onego Bio secures €14M / $15.2M new funding to advance animal-free egg protein production.

An industry disruptor, Onego Bio, has completed Series A funding round – one of the largest in the Nordics - for scaling its revolutionary animal-free egg protein, Bioalbumen®

The world deserves a way to produce our beloved egg protein without the hefty burden of animal agriculture – luckily, we know a better way. Read more how we cracked the code to produce animal-free egg protein!